Çek Cumhuriyeti - Çekçe - SUKL (Státní ústav pro kontrolu léčiv)

orion corporation, espoo array - 588 alprazolam - tableta - 0,25mg - alprazolam

Çek Cumhuriyeti - Çekçe - SUKL (Státní ústav pro kontrolu léčiv)

orion corporation, espoo array - 588 alprazolam - tableta - 0,5mg - alprazolam

Çek Cumhuriyeti - Çekçe - SUKL (Státní ústav pro kontrolu léčiv)

orion corporation, espoo array - 588 alprazolam - tableta - 1mg - alprazolam

Çek Cumhuriyeti - Çekçe - SUKL (Státní ústav pro kontrolu léčiv)

sanofi s.r.o., praha array - 9507 glimepirid - tableta - 2mg - glimepirid

Çek Cumhuriyeti - Çekçe - SUKL (Státní ústav pro kontrolu léčiv)

sanofi s.r.o., praha array - 9507 glimepirid - tableta - 3mg - glimepirid

Çek Cumhuriyeti - Çekçe - SUKL (Státní ústav pro kontrolu léčiv)

fresenius kabi ab, uppsala array - 4957 monohydrÁt glukosy; 1354 ČiŠtĚnÝ sÓjovÝ olej; 27 alanin; 96 arginin; 103 kyselina asparagovÁ; 665 kyselina glutamovÁ; 55 glycin; 717 histidin; 790 isoleucin; 829 leucin; 851 lysin-hydrochlorid; 2445 methionin; 1117 fenylalanin; 4147 prolin; 4717 serin; 1459 threonin; 1503 tryptofan; 1507 tyrosin; 1514 valin; 5599 dihydrÁt chloridu vÁpenatÉho; 16396 natrium-glycerofosfÁt; 864 heptahydrÁt sÍranu hoŘeČnatÉho; 1174 chlorid draselnÝ; 1306 trihydrÁt natrium-acetÁtu - infuzní emulze - roztoky pro parenterÁlnÍ vÝŽivu, kombinace

Çek Cumhuriyeti - Çekçe - SUKL (Státní ústav pro kontrolu léčiv)

fresenius kabi ab, uppsala array - 4957 monohydrÁt glukosy; 1354 ČiŠtĚnÝ sÓjovÝ olej; 27 alanin; 96 arginin; 103 kyselina asparagovÁ; 665 kyselina glutamovÁ; 55 glycin; 717 histidin; 790 isoleucin; 829 leucin; 851 lysin-hydrochlorid; 2445 methionin; 1117 fenylalanin; 4147 prolin; 4717 serin; 1459 threonin; 1503 tryptofan; 1507 tyrosin; 1514 valin; 5599 dihydrÁt chloridu vÁpenatÉho; 16396 natrium-glycerofosfÁt; 864 heptahydrÁt sÍranu hoŘeČnatÉho; 1174 chlorid draselnÝ; 1306 trihydrÁt natrium-acetÁtu - infuzní emulze - roztoky pro parenterÁlnÍ vÝŽivu, kombinace

Avrupa Birliği - Çekçe - EMA (European Medicines Agency)

virbac s.a. - recombinant omega interferon of feline origin - immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. in cats infected by fiv, mortality was low (5%) and was not influenced by the treatment.